Tubize-Fin (TUB) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.051x

Based on the latest financial reports, Tubize-Fin (TUB) has a cash flow conversion efficiency ratio of 0.051x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€100.76 Million ≈ $117.80 Million USD) by net assets (€1.99 Billion ≈ $2.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TUB company net worth for the company's overall valuation and market capitalisation.

Tubize-Fin - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Tubize-Fin's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tubize-Fin Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tubize-Fin ranked by their cash flow conversion efficiency. Explore Tubize-Fin (TUB) cash earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Eastroc Beverage Group Co Ltd
SHG:605499
0.071x
Frontline Ltd
NYSE:FRO
0.113x
Ramsay Health Care Ltd
AU:RHC
0.062x
Banca Transilvania S.A.
RO:TLV
0.028x
Engie Brasil Energia S.A.
SA:EGIE3
0.078x
ENN Ecological Holdings Co Ltd
SHG:600803
0.023x
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
N/A
Orion Oyj B
HE:ORNBV
0.086x

Annual Cash Flow Conversion Efficiency for Tubize-Fin (2004–2025)

The table below shows the annual cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. View current stock price of Tubize-Fin for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €1.89 Billion
≈ $2.20 Billion
€91.84 Million
≈ $107.37 Million
0.049x +4432.70%
2024-12-31 €1.84 Billion
≈ $2.15 Billion
€-2.07 Million
≈ $-2.42 Million
-0.001x +1.28%
2023-12-31 €1.80 Billion
≈ $2.10 Billion
€-2.05 Million
≈ $-2.39 Million
-0.001x -101.14%
2022-12-31 €1.75 Billion
≈ $2.05 Billion
€174.23 Million
≈ $203.69 Million
0.099x +27868.38%
2021-12-31 €3.25 Billion
≈ $3.80 Billion
€-1.16 Million
≈ $-1.36 Million
0.000x +52.23%
2020-12-31 €2.79 Billion
≈ $3.27 Billion
€-2.09 Million
≈ $-2.45 Million
-0.001x -74.16%
2019-12-31 €2.66 Billion
≈ $3.11 Billion
€-1.15 Million
≈ $-1.34 Million
0.000x -101.33%
2018-12-31 €2.34 Billion
≈ $2.74 Billion
€75.76 Million
≈ $88.57 Million
0.032x -6.11%
2017-12-31 €2.12 Billion
≈ $2.47 Billion
€72.96 Million
≈ $85.30 Million
0.034x -0.28%
2016-12-31 €1.96 Billion
≈ $2.29 Billion
€67.70 Million
≈ $79.15 Million
0.035x +6.14%
2015-12-31 €1.95 Billion
≈ $2.28 Billion
€63.45 Million
≈ $74.18 Million
0.033x +8720.77%
2014-12-31 €1.62 Billion
≈ $1.90 Billion
€-613.00K
≈ $-716.66K
0.000x +28.75%
2013-12-31 €1.55 Billion
≈ $1.81 Billion
€-823.00K
≈ $-962.17K
-0.001x +43.61%
2012-12-31 €1.49 Billion
≈ $1.74 Billion
€-1.40 Million
≈ $-1.64 Million
-0.001x -1274.66%
2011-12-31 €1.55 Billion
≈ $1.81 Billion
€124.00K
≈ $144.97K
0.000x +110.32%
2010-12-31 €1.44 Billion
≈ $1.69 Billion
€-1.12 Million
≈ $-1.31 Million
-0.001x +91.77%
2009-12-31 €1.36 Billion
≈ $1.59 Billion
€-12.79 Million
≈ $-14.96 Million
-0.009x -311.75%
2008-12-31 €1.20 Billion
≈ $1.40 Billion
€5.32 Million
≈ $6.22 Million
0.004x +0.18%
2007-12-31 €1.26 Billion
≈ $1.47 Billion
€5.61 Million
≈ $6.55 Million
0.004x -98.16%
2006-12-31 €1.36 Billion
≈ $1.58 Billion
€327.96 Million
≈ $383.42 Million
0.242x +1799.40%
2005-12-31 €901.39 Million
≈ $1.05 Billion
€-12.84 Million
≈ $-15.01 Million
-0.014x -376.61%
2004-12-31 €592.56 Million
≈ $692.76 Million
€3.05 Million
≈ $3.57 Million
0.005x --

About Tubize-Fin

BR:TUB Belgium Biotechnology
Market Cap
$9.26 Billion
€7.92 Billion EUR
Market Cap Rank
#2527 Global
#11 in Belgium
Share Price
€178.00
Change (1 day)
-0.34%
52-Week Range
€158.60 - €247.50
All Time High
€247.50
About

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.